Drug Trial Radar · NCT06451770
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
132
Planned (sponsor's estimate)
Start
Oct 30, 2024
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jun 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia. VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.
Conditions
- Hypercholesterolemia
- Hypertriglyceridemia
- Refractory Hyperlipidemia
Interventions
VERVE-201Drug
Intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: Up to Day 365
Locations
18 sites in 6 countries. Site status is shown where the registry gives one.
Clinical Study Center
Garden Grove, California · Recruiting
Clinical Study Center
Clearwater, Florida · Recruiting
Clinical Study Center
Miami Lakes, Florida · Recruiting
Clinical Study Center
Port Orange, Florida · Recruiting
Clinical Study Center
New York, New York · Recruiting
Clinical Study Center
Adelaide, Australia · Recruiting
Clinical Study Center
Melbourne, Australia · Recruiting
Clinical Study Center
Chicoutimi, Canada · Recruiting
Clinical Study Center
Montreal, Canada · Recruiting
Clinical Study Center
Toronto, Canada · Recruiting
Clinical Study Center
Amsterdam, Netherlands · Recruiting
Clinical Study Center
Rotterdam, Netherlands · Recruiting
Clinical Study Center
Cape Town, South Africa · Recruiting
Clinical Study Center
Johannesburg, South Africa · Recruiting
Clinical Study Center
Liverpool, United Kingdom · Recruiting
Clinical Study Center
London, United Kingdom · Recruiting
Clinical Study Center 2
Manchester, United Kingdom · Recruiting
Clinical Study Center
Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.